Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 20/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 20/20 | 0.67 |
| ▸ | ADRA1B | P35368 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5102068 | 0.85 | DRD2 (0.54) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL3865823 | 0.82 | KDM1A (0.52) | DRD2 | |
| SCHEMBL13866645 | 0.81 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL13866646 | 0.81 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL13866670 | 0.80 | ADRA1D (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL3863575 | 0.80 | ADRA1D (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL13866668 | 0.80 | ADRA1D (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL13866697 | 0.80 | ADRA1D (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL13866669 | 0.80 | ADRA1D (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL20129730 | 0.80 | CKS1B (0.51) | DRD2ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517885-B2 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-14 | — | — | US | disclosed |
| US-7517885-B2 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-14 | — | — | US | disclosed |
| US-7517885-B2 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-14 | — | — | US | disclosed |
| US-7459557-B2 | Substituted isoindole-1,3-diones | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-12-02 | — | — | US | disclosed |
| US-7459557-B2 | Substituted isoindole-1,3-diones | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-12-02 | — | — | US | disclosed |
| US-7459557-B2 | Substituted isoindole-1,3-diones | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-12-02 | — | — | US | disclosed |
| US-20070123542-A1 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | CHIU GEORGE | 2007-05-31 | — | — | US | disclosed |
| US-20070123542-A1 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | CHIU GEORGE | 2007-05-31 | — | — | US | disclosed |
| US-20070123542-A1 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | CHIU GEORGE | 2007-05-31 | — | — | US | disclosed |
| US-20070093500-A1 | Substituted isoindole-1,3-diones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093500-A1 | Substituted isoindole-1,3-diones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093500-A1 | Substituted isoindole-1,3-diones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | US | disclosed |
| WO-2007005214-A1 | SUBSTITUTED {4(4-PHENYL-PIPERAZIN-1YL)-CYCLOHEXYL}-UREA COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005214-A1 | SUBSTITUTED {4(4-PHENYL-PIPERAZIN-1YL)-CYCLOHEXYL}-UREA COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007001818-A2 | SUBSTITUTED ISOINDOLE-1,3-DIONES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123542-A1 | Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds | ADRA1D, ADRA1A, ADRB1 | DRD2 662/4885ADRA1D 1/4885ADRA1A 2/4885 |
| US-20070093500-A1 | Substituted isoindole-1,3-diones | ADRA1D, ADRA1A, ADRB1 | DRD2 94/4885ADRA1D 1/4885ADRA1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.